ZARZA We are Zarza, the prestigious firm behind major projects in information technology.
Listen "New Tests Predict Heart Transplant Risk 11/27/25"
Episode Synopsis
Welcome to Cardiology Today – Recorded November 27, 2025. This episode summarizes 5 key cardiology studies on topics like Gene expression profiling and Graft survival. Key takeaway: New Tests Predict Heart Transplant Risk.
Article Links:
Article 1: Trends in Prevalence, Treatment, and Control of Cardiometabolic Risk Factors Among Adults With Hypertension in the United States, 1999-2023. (Journal of the American College of Cardiology)
Article 2: Multimodal Molecular Testing Provides Prognostic Value for Heart Transplant Recipients. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 3: Results of the MACiTEPH study of macitentan for the treatment of inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 4: Enhancement of suppressive function of Ly49+ CD8+ T cells in allogeneic immunity by CD80/86-CD28 blockade in mouse. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 5: Fifty-Year Pediatric Heart Transplant Outcomes: A Pediatric-Adult Center Linked Analysis. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Full episode page: https://podcast.explainheart.com/podcast/new-tests-predict-heart-transplant-risk-11-27-25/
Featured Articles
Article 1: Trends in Prevalence, Treatment, and Control of Cardiometabolic Risk Factors Among Adults With Hypertension in the United States, 1999-2023.
Journal: Journal of the American College of Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41295934
Summary: The United States observed a sharp increase in hypertension-related deaths over the past decade, underscoring the need for public health strategies. This study identified 21822 adults with hypertension from 1999 to 2023 through the National Health and Nutrition Examination Survey. Researchers collected data on changes in age-adjusted prevalence of diabetes and other cardiometabolic risk factors within this population. The analysis of these trends offers critical insights into the evolving landscape of hypertension management.
Article 2: Multimodal Molecular Testing Provides Prognostic Value for Heart Transplant Recipients.
Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41297735
Summary: Multimodal molecular testing with gene expression profiling and donor-derived cell-free deoxyribonucleic acid demonstrated prognostic value for heart transplant recipients. This study evaluated 1934 patients from the Surveillance HeartCare Outcomes Registry. Researchers assessed risk based on the most abnormal test results between two and six months post-transplant. The evaluation provided insights into the joint ability of these molecular tests to predict future clinical events, such as graft dysfunction.
Article 3: Results of the MACiTEPH study of macitentan for the treatment of inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension.
Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41297734
Summary: The MACiTEPH study evaluated macitentan 75 milligrams once daily for treating inoperable or persistent or recurrent chronic thromboembolic pulmonary hypertension. This prospective, double-blind, placebo-controlled, phase three study randomized adult patients one to one to macitentan or placebo. The patient population included individuals with chronic thromboembolic pulmonary hypertension, with or without balloon pulmonary angioplasty, or after pulmonary endarterectomy. The primary endpoint for this investigation was a clinical composite.
Article 4: Enhancement of suppressive function of Ly49+ CD8+ T cells in allogeneic immunity by CD80/86-CD28 blockade in mouse.
Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41297733
Summary: Ly49 positive C D 8 positive T cells restricted by Qa-1 or major histocompatibility complex peptide function as immune suppressors in allogeneic immunity. In organ transplantation, a C-X-C motif chemokine receptor 5 positive Ly49 positive C D 8 positive T cell subset suppresses C D 4 positive T cell activation through Qa-1 recognition. This action inhibits donor-specific antibody production and promotes heart graft survival. This suppressive effect is particularly enhanced under C D 80/86-C D 28 co-blockade.
Article 5: Fifty-Year Pediatric Heart Transplant Outcomes: A Pediatric-Adult Center Linked Analysis.
Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41297732
Summary: This study analyzed fifty-year outcomes following pediatric heart transplant using a pediatric-adult center linked analysis. Researchers reviewed all pediatric heart transplants performed at Stanford from August 19 1974 to August 19 2024, leveraging a linked electronic medical record system. The analysis documented patient characteristics and post-transplant outcomes, including death and retransplant. This extensive review provided a detailed understanding of long-term patient trajectories, including events after adult care transfer.
Transcript
Today’s date is November 27, 2025. Welcome to Cardiology Today. Here are the latest research findings.
Article number one. Trends in Prevalence, Treatment, and Control of Cardiometabolic Risk Factors Among Adults With Hypertension in the United States, 1999-2023. The United States observed a sharp increase in hypertension-related deaths over the past decade, underscoring the need for public health strategies. This study identified 21822 adults with hypertension from 1999 to 2023 through the National Health and Nutrition Examination Survey. Researchers collected data on changes in age-adjusted prevalence of diabetes and other cardiometabolic risk factors within this population. The analysis of these trends offers critical insights into the evolving landscape of hypertension management.
Article number two. Multimodal Molecular Testing Provides Prognostic Value for Heart Transplant Recipients. Multimodal molecular testing with gene expression profiling and donor-derived cell-free deoxyribonucleic acid demonstrated prognostic value for heart transplant recipients. This study evaluated 1934 patients from the Surveillance HeartCare Outcomes Registry. Researchers assessed risk based on the most abnormal test results between two and six months post-transplant. The evaluation provided insights into the joint ability of these molecular tests to predict future clinical events, such as graft dysfunction.
Article number three. Results of the MACiTEPH study of macitentan for the treatment of inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension. The MACiTEPH study evaluated macitentan 75 milligrams once daily for treating inoperable or persistent or recurrent chronic thromboembolic pulmonary hypertension. This prospective, double-blind, placebo-controlled, phase three study randomized adult patients one to one to macitentan or placebo. The patient population included individuals with chronic thromboembolic pulmonary hypertension, with or without balloon pulmonary angioplasty, or after pulmonary endarterectomy. The primary endpoint for this investigation was a clinical composite.
Article number four. Enhancement of suppressive function of Ly49+ CD8+ T cells in allogeneic immunity by CD80/86-CD28 blockade in mouse. Ly49 positive C D 8 positive T cells restricted by Qa-1 or major histocompatibility complex peptide function as immune suppressors in allogeneic immunity. In organ transplantation, a C-X-C motif chemokine receptor 5 positive Ly49 positive C D 8 positive T cell subset suppresses C D 4 positive T cell activation through Qa-1 recognition. This action inhibits donor-specific antibody production and promotes heart graft survival. This suppressive effect is particularly enhanced under C D 80/86-C D 28 co-blockade.
Article number five. Fifty-Year Pediatric Heart Transplant Outcomes: A Pediatric-Adult Center Linked Analysis. This study analyzed fifty-year outcomes following pediatric heart transplant using a pediatric-adult center linked analysis. Researchers reviewed all pediatric heart transplants performed at Stanford from August 19 1974 to August 19 2024, leveraging a linked electronic medical record system. The analysis documented patient characteristics and post-transplant outcomes, including death and retransplant. This extensive review provided a detailed understanding of long-term patient trajectories, including events after adult care transfer.
Thank you for listening. Don’t forget to subscribe.
Keywords
Gene expression profiling, Graft survival, Donor-derived cell-free deoxyribonucleic acid, Long-term outcomes, Prognostic value, Diabetes, Allogeneic immunity, Donor-specific antibody, Retransplant, Pediatric heart transplant, Public health, Adult care transition, Cardiometabolic risk factors, Balloon pulmonary angioplasty, Macitentan, Chronic thromboembolic pulmonary hypertension, Electronic medical record, Pulmonary endarterectomy, National Health and Nutrition Examination Survey, Heart transplant, Graft dysfunction, Immunosuppression, Hypertension, Phase three trial, C D 8 positive T cells.
About
Concise summaries of cardiovascular research for professionals.
Subscribe • Share • FollowThe post New Tests Predict Heart Transplant Risk 11/27/25 first appeared on Cardiology Today.
Article Links:
Article 1: Trends in Prevalence, Treatment, and Control of Cardiometabolic Risk Factors Among Adults With Hypertension in the United States, 1999-2023. (Journal of the American College of Cardiology)
Article 2: Multimodal Molecular Testing Provides Prognostic Value for Heart Transplant Recipients. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 3: Results of the MACiTEPH study of macitentan for the treatment of inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 4: Enhancement of suppressive function of Ly49+ CD8+ T cells in allogeneic immunity by CD80/86-CD28 blockade in mouse. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 5: Fifty-Year Pediatric Heart Transplant Outcomes: A Pediatric-Adult Center Linked Analysis. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Full episode page: https://podcast.explainheart.com/podcast/new-tests-predict-heart-transplant-risk-11-27-25/
Featured Articles
Article 1: Trends in Prevalence, Treatment, and Control of Cardiometabolic Risk Factors Among Adults With Hypertension in the United States, 1999-2023.
Journal: Journal of the American College of Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41295934
Summary: The United States observed a sharp increase in hypertension-related deaths over the past decade, underscoring the need for public health strategies. This study identified 21822 adults with hypertension from 1999 to 2023 through the National Health and Nutrition Examination Survey. Researchers collected data on changes in age-adjusted prevalence of diabetes and other cardiometabolic risk factors within this population. The analysis of these trends offers critical insights into the evolving landscape of hypertension management.
Article 2: Multimodal Molecular Testing Provides Prognostic Value for Heart Transplant Recipients.
Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41297735
Summary: Multimodal molecular testing with gene expression profiling and donor-derived cell-free deoxyribonucleic acid demonstrated prognostic value for heart transplant recipients. This study evaluated 1934 patients from the Surveillance HeartCare Outcomes Registry. Researchers assessed risk based on the most abnormal test results between two and six months post-transplant. The evaluation provided insights into the joint ability of these molecular tests to predict future clinical events, such as graft dysfunction.
Article 3: Results of the MACiTEPH study of macitentan for the treatment of inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension.
Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41297734
Summary: The MACiTEPH study evaluated macitentan 75 milligrams once daily for treating inoperable or persistent or recurrent chronic thromboembolic pulmonary hypertension. This prospective, double-blind, placebo-controlled, phase three study randomized adult patients one to one to macitentan or placebo. The patient population included individuals with chronic thromboembolic pulmonary hypertension, with or without balloon pulmonary angioplasty, or after pulmonary endarterectomy. The primary endpoint for this investigation was a clinical composite.
Article 4: Enhancement of suppressive function of Ly49+ CD8+ T cells in allogeneic immunity by CD80/86-CD28 blockade in mouse.
Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41297733
Summary: Ly49 positive C D 8 positive T cells restricted by Qa-1 or major histocompatibility complex peptide function as immune suppressors in allogeneic immunity. In organ transplantation, a C-X-C motif chemokine receptor 5 positive Ly49 positive C D 8 positive T cell subset suppresses C D 4 positive T cell activation through Qa-1 recognition. This action inhibits donor-specific antibody production and promotes heart graft survival. This suppressive effect is particularly enhanced under C D 80/86-C D 28 co-blockade.
Article 5: Fifty-Year Pediatric Heart Transplant Outcomes: A Pediatric-Adult Center Linked Analysis.
Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41297732
Summary: This study analyzed fifty-year outcomes following pediatric heart transplant using a pediatric-adult center linked analysis. Researchers reviewed all pediatric heart transplants performed at Stanford from August 19 1974 to August 19 2024, leveraging a linked electronic medical record system. The analysis documented patient characteristics and post-transplant outcomes, including death and retransplant. This extensive review provided a detailed understanding of long-term patient trajectories, including events after adult care transfer.
Transcript
Today’s date is November 27, 2025. Welcome to Cardiology Today. Here are the latest research findings.
Article number one. Trends in Prevalence, Treatment, and Control of Cardiometabolic Risk Factors Among Adults With Hypertension in the United States, 1999-2023. The United States observed a sharp increase in hypertension-related deaths over the past decade, underscoring the need for public health strategies. This study identified 21822 adults with hypertension from 1999 to 2023 through the National Health and Nutrition Examination Survey. Researchers collected data on changes in age-adjusted prevalence of diabetes and other cardiometabolic risk factors within this population. The analysis of these trends offers critical insights into the evolving landscape of hypertension management.
Article number two. Multimodal Molecular Testing Provides Prognostic Value for Heart Transplant Recipients. Multimodal molecular testing with gene expression profiling and donor-derived cell-free deoxyribonucleic acid demonstrated prognostic value for heart transplant recipients. This study evaluated 1934 patients from the Surveillance HeartCare Outcomes Registry. Researchers assessed risk based on the most abnormal test results between two and six months post-transplant. The evaluation provided insights into the joint ability of these molecular tests to predict future clinical events, such as graft dysfunction.
Article number three. Results of the MACiTEPH study of macitentan for the treatment of inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension. The MACiTEPH study evaluated macitentan 75 milligrams once daily for treating inoperable or persistent or recurrent chronic thromboembolic pulmonary hypertension. This prospective, double-blind, placebo-controlled, phase three study randomized adult patients one to one to macitentan or placebo. The patient population included individuals with chronic thromboembolic pulmonary hypertension, with or without balloon pulmonary angioplasty, or after pulmonary endarterectomy. The primary endpoint for this investigation was a clinical composite.
Article number four. Enhancement of suppressive function of Ly49+ CD8+ T cells in allogeneic immunity by CD80/86-CD28 blockade in mouse. Ly49 positive C D 8 positive T cells restricted by Qa-1 or major histocompatibility complex peptide function as immune suppressors in allogeneic immunity. In organ transplantation, a C-X-C motif chemokine receptor 5 positive Ly49 positive C D 8 positive T cell subset suppresses C D 4 positive T cell activation through Qa-1 recognition. This action inhibits donor-specific antibody production and promotes heart graft survival. This suppressive effect is particularly enhanced under C D 80/86-C D 28 co-blockade.
Article number five. Fifty-Year Pediatric Heart Transplant Outcomes: A Pediatric-Adult Center Linked Analysis. This study analyzed fifty-year outcomes following pediatric heart transplant using a pediatric-adult center linked analysis. Researchers reviewed all pediatric heart transplants performed at Stanford from August 19 1974 to August 19 2024, leveraging a linked electronic medical record system. The analysis documented patient characteristics and post-transplant outcomes, including death and retransplant. This extensive review provided a detailed understanding of long-term patient trajectories, including events after adult care transfer.
Thank you for listening. Don’t forget to subscribe.
Keywords
Gene expression profiling, Graft survival, Donor-derived cell-free deoxyribonucleic acid, Long-term outcomes, Prognostic value, Diabetes, Allogeneic immunity, Donor-specific antibody, Retransplant, Pediatric heart transplant, Public health, Adult care transition, Cardiometabolic risk factors, Balloon pulmonary angioplasty, Macitentan, Chronic thromboembolic pulmonary hypertension, Electronic medical record, Pulmonary endarterectomy, National Health and Nutrition Examination Survey, Heart transplant, Graft dysfunction, Immunosuppression, Hypertension, Phase three trial, C D 8 positive T cells.
About
Concise summaries of cardiovascular research for professionals.
Subscribe • Share • FollowThe post New Tests Predict Heart Transplant Risk 11/27/25 first appeared on Cardiology Today.
More episodes of the podcast Cardiology Today
Underweight Risk in Type 2 Diabetes 11/25/25
25/11/2025
In God we trust